Lipocine (LPCN) Getting Somewhat Favorable Press Coverage, Analysis Finds

News articles about Lipocine (NASDAQ:LPCN) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lipocine earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 47.3052846301292 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Lipocine traded up $0.07, reaching $1.30, during midday trading on Friday, Marketbeat.com reports. 291,860 shares of the stock were exchanged, compared to its average volume of 492,174. The company has a current ratio of 5.03, a quick ratio of 5.04 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $26.16 million, a PE ratio of -1.24 and a beta of 0.52. Lipocine has a 52 week low of $1.03 and a 52 week high of $5.33.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, May 7th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.08. The firm had revenue of $0.43 million for the quarter. research analysts forecast that Lipocine will post -0.92 earnings per share for the current year.

LPCN has been the topic of several research reports. HC Wainwright set a $3.00 price target on shares of Lipocine and gave the company a “buy” rating in a research report on Thursday, May 10th. ValuEngine raised shares of Lipocine from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 8th. Seaport Global Securities initiated coverage on shares of Lipocine in a research report on Thursday, March 29th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Canaccord Genuity reissued a “hold” rating and issued a $2.00 price target on shares of Lipocine in a research report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $12.80.

About Lipocine

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Insider Buying and Selling by Quarter for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply